ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Clinical characteristics and treatment of low-dose methotrexate-related adverse reactions in rheumatoid arthritis: a retrospective study.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Low-dose methotrexate (MTX) (5-25 mg/week) is widely used in the treatment of autoimmune diseases and is considered relatively safe. There have been reports of toxicities caused by MTX, but the characteristics remain unclear. Through a retrospective case series at our hospital, we describe the clinical features, management, and outcomes of adverse reactions caused by MTX. This is a retrospective, single-center case series of patients with rheumatoid arthritis (RA) who developed adverse reactions while receiving low-dose MTX (5-25 mg/week) between March 2022 and August 2025. Exclusion criteria included adverse reactions due to other drugs, viral infections, or vitamin B12/folate deficiency. We present only descriptive statistics (median, range, frequency). The series included 18 patients. Of these, 77.78% were female. Median age was 72 years (51-77 years). Median MTX dosage was 10 mg (7.5-35 mg) weekly. Adverse reactions involved multiple organ systems. Hematological adverse reactions were primarily characterized by cytopenia, anemia, and bleeding. Gastrointestinal adverse reactions were nausea and vomiting. Skin-related adverse reactions included skin ulcers, erythema, swelling, and pain. Leucovorin calcium rescue therapy via intravenous administration was given in 77.78% of patients. Additionally, 9 patients (50.00%) required blood transfusion, 8 patients (44.44%) received recombinant human granulocyte-stimulating factor, and 5 patients (27.78%) were treated with sodium bicarbonate for urine alkalization. During hospitalization, 2 patients (11.11%) died, both due to severe infectious complications. Most adverse reactions caused by low-dose MTX were manageable with supportive care. However, severe toxicity (including fatalities) occurred in elderly or frail patients. Serum MTX concentration showed inconsistent associations with adverse reactions and should not be relied upon to predict low-dose MTX toxicity.
Indexed as
Identifiers
42240664What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.